Gamifant Patient Services
is the first
and only FDA-approved
treatment for patients with
primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent, or progressive disease or
intolerance with conventional HLH therapy.
Starting my primary HLH
Learn about the disease, symptoms, and treatment options
Already taking or considering Gamifant
See if Gamifant is the right treatment option for you or your child
Looking for support and guidance
Find other resources and support networks that could be helpful
This website is intended for US healthcare providers. By continuing, you confirm you are a healthcare
You are being redirected to a third party website.
Sobi takes no responsibility for the content of this website.